MOBE Expands Digital Multi-Condition Platform With Pain, MSK, MASLD, and MASH Support
Multiple new digital experiences join MOBE’s library of 36 clinically supported conditions and health concerns—each addressing a high-prevalence condition that rarely occurs on its own.
MINNEAPOLIS—April 22, 2026—MOBE, the whole-person condition management company, announced today the inclusion of pain management, musculoskeletal health (MSK), metabolic dysfunction-associated steatotic liver disease (MASLD), and metabolic dysfunction-associated steatohepatitis (MASH) to its digital multi-condition management platform designed by Sidekick Health. These additions join a library of more than 36 conditions and health concerns already supported by MOBE's integrated human and digital experience. It’s built for the reality that most individuals managing one of these conditions are simultaneously managing several others.
More than half of Americans live with two or more chronic conditions.1 The conditions added today are among the most common and consequential contributors to multi-chronic complexity. MSK disorders affect more than one in three American adults, MASLD affects an estimated 25–30% of the U.S. population, and up to 5% live with MASH.2,3,4
“What makes these conditions particularly complex to support is how they interact with other conditions in addition to their individual burden. On average, MOBE-identified individuals live with four or more chronic conditions, making integrated, cross-condition care a necessary feature for sustained support,” said Leslie Helou, PharmD, Senior Vice President of Health Outcomes Strategy at MOBE.
In the MOBE-identified population, 75% of participants manage pain resulting from MSK conditions. Around 20% of participants have type 2 diabetes, a common risk factor for more severe liver disease, and nearly 10% have known MASLD or MASH. “The broad, significant impact these new digital experiences will have on our population’s health outcomes and our partner’s total cost of care cannot be understated,” Helou said.
MSK disorders are the leading cause of disability in the U.S. and account for nearly 10% of national medical spending.5 The incidence of MSK disorders is projected to rise further as the population ages and rates of multiple chronic conditions increase. Yet the standard treatment path remains poorly suited to this population. Common problems with MSK care include the overutilization of imaging, surgery, and opioids.6
MSK disorders do not occur in isolation as 46% of individuals with MSK pain have comorbidities including hypertension, diabetes, anxiety, and depression.7 Chronic MSK pain is also associated with fatigue, sleep disruption, and—when undertreated—opioid dependence.8
Three-quarters of MOBE-identified individuals are managing MSK pain. MOBE’s new MSK digital experience integrates with its pre-existing human-led MSK support. MOBE Guides bring a biopsychosocial framework to pain management that goes beyond symptom relief to improve participants’ functional outcomes and overall well-being. MOBE Pharmacists provide clinical expertise in pain management and medication optimization, to help individuals navigate opioid use and identify interactions with other medications, supplements, and over-the-counter products. Chronic pain is a complex experience that demands an integrated, cross-condition approach—which MOBE is built to deliver.
MASLD and MASH represent a spectrum of progressive liver conditions. MASLD affects 60–70% of people with type 2 diabetes and 80–90% of people with obesity.9 MASLD is now among the leading causes of liver transplantation—especially in women and increasingly across older and metabolically complex populations.10 MASH, the more severe form of MASLD, is projected to affect tens of millions of Americans by 2030. Per-patient health care costs are expected to rise significantly as disease severity increases.11
The risk profile for MASLD reflects the multi-chronic individual. It includes obesity, type 2 diabetes or prediabetes, high blood pressure, high triglycerides, and low HDL cholesterol and is often paired with behaviors like inactivity, smoking, and diets high in processed foods.9 Referred to as “silent liver disease,” MASLD’s asymptomatic nature highlights the importance of early and sustained lifestyle intervention to reduce the risk of severe progression.
MASLD and MASH are natural additions to MOBE’s multi-condition care model, and these new digital experiences integrate with its existing human-led cardiometabolic support offerings. Peer-reviewed research found engagement in a digital program led to meaningful, sustained improvements in liver and cardiometabolic health markers over nine months.12 MOBE Guides and Pharmacists are uniquely positioned to support the lifestyle, medication, and behavioral changes that drive outcomes in liver disease and to do so in the context of diabetes, obesity, and cardiovascular conditions that often accompany it.
For employers and health plans, the clinical and financial case for addressing MSK, chronic pain, and MASLD with a whole-person approach is clear. When MSK pain worsens depression, or when MASLD and diabetes accelerate disease progression, or when opioids prescribed for pain interact with medications prescribed for a liver condition, the costs of treating each health issue individually mount quickly. Supporting these conditions as connected components of an individual’s overall health, rather than in isolation, leads to better outcomes and lower total cost of care.
MOBE is excited to offer a clinically grounded, digitally innovative solution that meets individuals managing these conditions where their health truly lives—at the intersection of multiple conditions, not at the edges of just one.
About MOBE
MOBE is a whole-person condition management company dedicated to helping individuals discover new ways to live healthier through personalized, evidence-based clinical and non-clinical interventions. Combining advanced data analytics, one-to-one health guidance, and digital tools, MOBE empowers individuals to optimize their physical health, mental well-being, and medication management. MOBE partners with employers and health plans to reduce health care claims costs by an average of 7.5% in the first year while enhancing participant satisfaction and well-being. Learn more at MOBEforlife.com.
References
1. Kathleen B. Watson et al., “Trends in Multiple Chronic Conditions Among US Adults, By Life Stage, Behavioral Risk Factor Surveillance System, 2013–2023,” Preventing Chronic Disease 22 (April 17, 2025), https://www.cdc.gov/pcd/issues/2025/24_0539.htm.
2. Andrew T. Nguyen et al., “Musculoskeletal Health: An Ecological Study Assessing Disease Burden and Research Funding,” The Lancet Regional Health – Americas 29 (January 8, 2024): 100661, https://doi.org/10.1016/j.lana.2023.100661.
3. Mary E. Rinella et al., “AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease,” Hepatology 77, no. 5 (May 2023): 1797–1835, https://doi.org/10.1097/HEP.0000000000000323.
4. Chris Estes et al., “Modeling the Epidemic of Nonalcoholic Fatty Liver Disease Demonstrates an Exponential Increase in Burden of Disease,” Hepatology 67, no. 1 (December 1, 2017): 123–133, https://doi.org/10.1002/hep.29466.
5. Peterson-KFF Health System Tracker, “Years Lived with Disability,” Peterson-KFF Health System Tracker, 2026, https://www.healthsystemtracker.org/indicator/health-well-being/years-lived-with-disability/.
6. Peterson Health Technology Institute, “Virtual Musculoskeletal (MSK) Solutions,” Peterson Health Technology Institute, last updated October 10, 2024, https://phti.org/assessment/virtual-msk-solutions/.
7. “The Prevalence and Pattern of Comorbid Long-Term Conditions with Low Back Pain and Osteoarthritis in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis,” International Journal of Health Promotion and Education (April 30, 2024): 1–25, https://doi.org/10.1080/14635240.2024.2332911.
8. Kirsti Krohn Garnæs et al., “Mental Health Among Patients with Chronic Musculoskeletal Pain and Its Relation to Number of Pain Sites and Pain Intensity: A Cross-Sectional Study Among Primary Health Care Patients,” BMC Musculoskeletal Disorders 23, no. 1115 (December 22, 2022), https://doi.org/10.1186/s12891-022-06051-9.
9. Vishnu Girish and Savio John, “Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD),” in StatPearls, updated August 9, 2025, StatPearls Publishing, https://www.ncbi.nlm.nih.gov/sites/books/NBK541033/.
10. Younossi, Z. M., M. Kalligeros, and L. Henry, “Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease,” Clinical and Molecular Hepatology 2024, https://pubmed.ncbi.nlm.nih.gov/39159948/.
11. Z.M. Younossi, et al., “Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data From Nine Countries,” Clinical Gastroenterology and Hepatology 24, no. 4 (April 2026): 1016–34, https://doi.org/10.1016/j.cgh.2025.09.002.
12. Sigridur Björnsdottir, et al., “Long-Term Feasibility and Outcomes of a Digital Health Program to Improve Liver Fat and Cardiometabolic Markers in Individuals With Nonalcoholic Fatty Liver Disease: Prospective Single-Arm Feasibility Study,” JMIR Cardio 9 (September 12, 2025): e72074, https://doi.org/10.2196/72074